Posted by Michael Wonder on 02 Jun 2017
European Commission approves Brineura (cerliponase alfa), the first treatment for CLN2 disease, a form of Batten disease and ultra-rare brain disorder in children
1 June 2017 - Dosing includes all ages from birth for this fatal and rapid paediatric neurodegenerative condition Brineura is among first therapies to go through EMA's new accelerated assessment process.
BioMarin today announced the European Commission has granted marketing authorisation for Brineura (cerliponase alfa), the first treatment approved in the European Union for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency. The dosing administration includes all ages from birth.
